Text Size

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

This study has been completed.
Sponsor:
Information provided by:
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT00832182
First received: January 29, 2009
Last updated: June 8, 2012
Last verified: September 2011
History of Changes

January 29, 2009
June 8, 2012
December 1999
November 2002   (final data collection date for primary outcome measure)
Number of hypoglycemic episodes and adverse events [ Time Frame: at 3 and 6 months and at the end of the trial ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00832182 on ClinicalTrials.gov Archive Site
  • HbA1c [ Time Frame: at 3 and 6 months and at the end of the trial ] [ Designated as safety issue: No ]
  • 9-point blood glucose profile [ Time Frame: at 3 and 6 months and at the end of the trial ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes
An Open-labelled, Non-randomized, Multi-centre, Multinational Extension Trial Assessing the Safety of Insulin Aspart in Patients With Type I Diabetes Treated With a Basal-bolus Regimen

This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the long-term safety of insulin aspart in the management of type 1 diabetes. An extension to the ANA/DCD/065 trial
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Diabetes
  • Diabetes Mellitus, Type 1
  • Drug: insulin aspart
  • Drug: insulin NPH
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
75
November 2002
November 2002   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  • The subject must have completed the ANA/DCD/065 trial

Exclusion Criteria:

  • Impaired hepatic function
  • Impaired renal function
  • Total daily insulin requirements of more than 1.4 U/kg
  • Cardiac problems
  • Uncontrolled hypertension
  • Known or suspected allergy to trial product or related products
  • Current hypoglycaemic unawareness as judged by the investigator
  • Known or suspect abuse of alcohol or narcotics
  • Women breastfeeding or having the intention of becoming pregnant, or if judged not to be using adequate contraceptive measures (adequate measures are intrauterine device (IUD), oral contraception and barrier methods)
  • Any condition that the Investigator and/or Sponsor feels would interfere with trial participation or evaluation of results
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Croatia,   Czech Republic,   Israel,   Russian Federation,   Slovenia
 
NCT00832182
ANA-1229
No
Public Access to Clinical Trials, Novo Nordisk A/S
Novo Nordisk
Not Provided
Study Director: Karin Kanc, MD, PhD Novo Nordisk
Novo Nordisk
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP